Kimmtrak
Kimmtrak ingredients
| Active ingredient | Strength |
|---|---|
| Tebentafusp | 100 ug/.5mL |
What Kimmtrak is used for
The FDA lists the approved uses on the official label (below). In the EU, tebentafusp is approved as Kimmtrak for:
Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Kimmtrak
- Generic name
- Tebentafusp
- Made by
- Immunocore Commercial LLC
- Forms
- Injection, Solution, Concentrate
- Given
- Intravenous
- Drug class
- Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager
- FDA approval
- Biologic licence (BLA) BLA761228
- On the US market since
- 2022
Official information
- Kimmtrak prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tebentafusp)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kimmtrak?
Kimmtrak (Tebentafusp) is a cancer medicine made by Immunocore Commercial LLC, approved by the US FDA.
What are the ingredients of Kimmtrak?
Kimmtrak contains Tebentafusp (100 ug/.5mL).
Is Kimmtrak approved in Europe?
The same active substance is approved in the EU as Kimmtrak.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA